Structure Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GPCR research report →
Range $70 – $111
Price Chart
About the company
Structure Therapeutics Inc. , an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R).
- CEO
- Raymond C. Stevens
- IPO
- 2023
- Employees
- 281
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on GPCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.59B
- P/E
- -9.14
- Fwd P/E
- 15.94
- PEG
- 0.65
- P/S
- 0.00
- P/B
- 1.49
- EV/EBITDA
- -6.25
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -16.91%
- ROIC
- -18.95%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-3,899,285+0.0%
- Op Income
- $-287,567,533
- Net Income
- $-141,202,000-15.2%
- EPS
- $-2.40-2.6%
- OCF Growth
- -90.5%
- FCF Growth
- -91.5%
- 52W High
- $94.90
- 52W Low
- $25.59
- 50D MA
- $44.28
- 200D MA
- $53.35
- Beta
- -1.52
- RSI (14)
- 18
- Avg Volume
- 941.82K
No earnings-call transcripts are available for GPCR yet.
- Free Float
- 95.1%
- Shares Outstanding
- 57.57M
- Float Shares
- 54.73M
of shares held by institutions
209 13F filers
Buy/sell ratio 0.48. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GPCR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas Richard CarperSenate · DE | Sell | Oct 4, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 7.81M | ▼ 593.14K |
| Wellington Management Group Llp | 7.38M | ▲ 119.15K |
| Avoro Capital Advisors LLC | 6.56M | 0 |
| Janus Henderson Group Ltd. | 5.35M | ▲ 264.83K |
| Jupiter Topco LLC | 5.20M | ▲ 5.20M |
| Deep Track Capital, LP | 4.74M | ▲ 460.22K |
| Bvf Inc/Il | 3.37M | ▼ 92.53K |
| Morgan Stanley | 2.81M | ▲ 501.18K |
| Orbimed Advisors LLC | 2.21M | ▲ 734.00K |
| Principal Financial Group Inc | 1.75M | ▼ 1.01K |
| American Century Companies Inc | 1.68M | ▲ 244.15K |
| Rtw Investments, LP | 1.61M | ▲ 1.61M |
Held by 125 ETFs
Biggest fund positions in GPCR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 26 | Coll Crespo Blas | other | 10,626 |
| Sep 21, 26 | Coll Crespo Blas | other | 12,024 |
| Sep 21, 26 | Coll Crespo Blas | other | 4,008 |
| Sep 21, 26 | Coll Crespo Blas | sell | 4,008 |
| Sep 1, 26 | Lin Xichen | other | 17,817 |
| Sep 1, 26 | Lin Xichen | other | 17,817 |
| Sep 1, 26 | Lin Xichen | other | 17,817 |
| Sep 1, 26 | Lin Xichen | other | 5,939 |
| Sep 1, 26 | Lin Xichen | sell | 1,300 |
| Sep 1, 26 | Lin Xichen | sell | 4,539 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GPCR coverage
Recent articles, reports, and earnings notes.
Want a deeper read on GPCR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Rated “Moderate Buy” by Sell-Side Brokerages
defenseworld.net · Sep 26
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
zacks.com · Sep 17
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Structure Therapeutics: The Amylin Data Changes The Math
seekingalpha.com · Sep 9
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
seekingalpha.com · Sep 8
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
zacks.com · Sep 8
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
globenewswire.com · Sep 8
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
globenewswire.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.